Cervomed Inc (CRVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,291 | -2,172 | -5,803 | -24,096 | -14,185 |
| Depreciation Amortization | N/A | N/A | N/A | 93 | 103 |
| Income taxes - deferred | N/A | N/A | N/A | -444 | -1,675 |
| Accounts payable and accrued liabilities | 849 | 565 | 79 | 605 | 951 |
| Other Working Capital | -441 | -261 | 380 | 356 | 1,469 |
| Other Operating Activity | -648 | -5,582 | 2,771 | 8,983 | -215 |
| Operating Cash Flow | $-16,531 | $-7,450 | $-2,573 | $-14,502 | $-13,553 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -28,661 | N/A | N/A | N/A | N/A |
| PPE Investments | N/A | N/A | N/A | 4 | N/A |
| Investing Cash Flow | $-28,661 | $N/A | $N/A | $4 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 11,888 | N/A | N/A | N/A |
| Common Stock Issued | 46,399 | 810 | N/A | 33,296 | 18,873 |
| Other Financing Activity | 0 | -1,549 | 0 | 0 | -982 |
| Financing Cash Flow | $46,399 | $11,149 | $N/A | $33,296 | $17,891 |
| Beginning Cash Position | 7,793 | 4,094 | 6,666 | 18,516 | 14,177 |
| End Cash Position | 9,000 | 7,793 | 4,094 | 37,314 | 18,516 |
| Net Cash Flow | $1,207 | $3,699 | $-2,573 | $18,798 | $4,338 |
| Free Cash Flow | |||||
| Operating Cash Flow | -16,531 | -7,450 | -2,573 | -14,502 | -13,553 |
| Free Cash Flow | -16,531 | -7,450 | -2,573 | -14,502 | -13,553 |